Regeneron pre-announces $127M R&D charge, cutting Q2 EPS by ~$1.00

Filed July 6, 2026 · Period ending July 6, 2026 · ~1 min read

Key Changes

• high

  Regeneron expects a $127M pre-tax IPR&D charge in Q2 2026 from up-front and opt-in payments under collaboration and licensing agreements, reducing both GAAP and non-GAAP EPS by approximately $1.00.

  Item 2.02 — Results of Operations and Financial Condition verify on EDGAR →
• medium

  The company defines acquired IPR&D charges to include asset acquisitions, up-front payments, opt-in payments, development milestones, and equity premiums tied to collaboration deals; does not forecast these due to uncertain timing and magnitude.

  Item 2.02 — Results of Operations and Financial Condition verify on EDGAR →
• low

  Q2 2026 results are preliminary and unaudited, subject to final closing procedures; actual results may differ from disclosed estimates.

  Item 2.02 — Results of Operations and Financial Condition verify on EDGAR →